Patent intelligence · US
US 7550503
Physiologically active substances
Physiologically active substances
Patent details — US 7550503
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 23, 2009
- Expiration
- Jun 18, 2029
- Applicant
- American Regent, Inc.
- Claims
- 26
- CPC classes
- A61K, A61K31/336, A61K31/366, A61K31/4025
Quick answer
US 7550503 (Physiologically active substances) is held by American Regent, Inc.. Status: granted. Granted Jun 23, 2009. Expires Jun 18, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- American Regent, Inc.
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K31/336, A61K31/366, A61K31/4025, A61K31/4427, A61K31/4523
More from American Regent, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 7550503?
US 7550503 (Physiologically active substances) is held by American Regent, Inc.. Status: granted. Granted Jun 23, 2009. Expires Jun 18, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7550503?
American Regent, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 7550503 expire?
Our index shows an expiration date of Jun 18, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.